The Future of Continuous Glucose Monitoring
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
More than three decades ago, when self-monitoring of blood glucose (SMBG) was first made available, most people doubted its uptake by questioning ‘‘who, why, and when?’’ Debates were around about why patients would poke their fingers few times a day and moreover, what will they do with the data? Today, it is the standard of care and was successfully used in the Diabetes Complications and Control Trial especially in the intensive arm. Most of the recent data from the type 1 diabetes (T1D) Exchange show increased SMBG monitoring results in better reduction of A1c in patients with T1D. Similar criticism surrounds continuous glucose monitoring (CGM) now. The first available retrospective CGM system was MiniMed iPro (nearly two decades ago) followed by the real-time display GlucoWatch in the year 2000 for 12 h using reversed iontophoresis. The next decade saw significant advances in CGM technologies by the Navigator (Abbott), Dexcom short-term sensor (STS), Gen 4 and 5 , and Medtronic Enlite and Guardian 3 . Most of the advances focused on improved accuracy where single digit mean absolute relative difference has become the standard, and in many instances, CGMs are now as accurate as SMBG. The early adoption of CGM was slow as expected with any new technology innovation. More recent data show a rapid increase in adoption rate across the United States and Western Europe, in part, due to improved accuracy and better coverage by the payers. As the number of patients using CGM increases, one hopes that the cost will go down. In this supplement, Graham discussed the challenges in the global reimbursement of CGM. In the future, CGM data will be available (currently only Dexcom Gen 5 ) on all mobile phones that use Bluetooth and insulin pumps without needing the data going through a receiver. Also, further advances in the technology will allow CGM to be used for 14 days without any calibration (factory calibration) or any need for an additional transmitter or receiver. After the 14-day use, the subject discards the whole CGM unit. As described by Hughes et al. in this supplement, once-daily calibrated real-time CGMs that have 10-day functional life may become available shortly. Currently, only FreeStyle Professional Libre (factory calibrated), flash glucose monitoring, is available in the US for 14 days for professional use. However, it is approved in Europe for personal use too. The flash glucose monitoring data are only available on demand and have no alarm feature. Please see the details of flash glucose monitoring in another supplement. It is also important to highlight that the future may see all CGM systems to be factory calibrated and data could be used to adjust insulin dose as a nonadjunctive device. Most patients do not use CGM as an adjunctive device to SMBG, and the Food and Drug Administration (FDA) recently approved Dexcom Gen 5 system data, which can be used as a nonadjunctive, except that it still needs calibration twice a day. Just like all patients with new-onset T1D get an SMBG meter today, we hope in the very near future, all patients with new-onset T1D will receive CGM. Forlenza et al. also emphasized challenges of the use of CGM in children and older adults in this supplement. The availability of CGMs has highlighted the deficiencies in following diabetes care based on A1c estimations. Glucose control measured by A1c values is a snapshot of overall glucose values for the past 1–3 months. It does not detect hypoglycemia or hyperglycemia on a day-to-day basis where patients need that information on a continual basis. The availability of CGM data has allowed patients and providers to not only improve glucose control but also reduce hypoglycemia and hyperglycemia across all ranges. This concept is further discussed in detail by Rodbard in this supplement. The CGM data can be summarized as glucose ranges (time in the range 70–180 mg/dL) and time spent above and below the target. Late last year, the FDA held a meeting in Washington, DC where the discussion was about moving beyond A1c.16 We hope the future will see time in range, above target range, and below target range as important tools to quantify glucose control like A1c on a day-to-day basis. Since A1c gives only a snapshot of overall glucose control, a new composite metric for the assessment of glucose control based on CGM data is explained by Hirsch et al. in this supplement. Another advantage of CGM use is alerts and alarms where subjects can be alarmed for impending hypoglycemia and hyperglycemia based on the rate of change of glucose, and thus patients can act accordingly. Using CGM may have great
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 1×
“Another advantage of CGM use is alerts and alarms where subjects can be alarmed for impending hypoglycemia and hyperglycemia based on the rate of change of glucose, and thus patients can act accordingly.(18,19) Using CGM may have great”
Self-citationDeiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Tierney, M. J., Tamada, J. A., Potts, R. O., Jovanovic, L., & Garg, S. (2001) · Biosensors and Bioelectronics · doi:10.1016/s0956-5663(01)00189-0 · Cited by 390
Self-citationAleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195 · cited 1×
“The availability of CGM data has allowed patients and providers to not only improve glucose control but also reduce hypoglycemia and hyperglycemia across all ranges.(13,14) This concept is further discussed in detail by Rodbard in this supplement.”
Bailey, T. S., Zisser, H. C., & Garg, S. K. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0205 · Cited by 159
Self-citation
Cited by
Blevins, T. C., Bode, B. W., Garg, S. K., Grunberger, G., Hirsch, I. B., Jovanovič, L., Nardacci, E., Orzeck, E. A., Roberts, V. L., & Tamborlane, W. V. (2010) · Endocrine Practice · doi:10.4158/ep.16.5.730 · Cited by 98
Self-citationGarg, S. K., Voelmle, M. K., Beatson, C. R., Miller, H. A., Crew, L. B., Freson, B. J., & Hazenfield, R. M. (2011) · Diabetes Care · doi:10.2337/dc10-1852 · Cited by 85
Self-citationNatale, P., Chen, S., Chow, C. K., Cheung, N. W., Martinez‐Martin, D., Caillaud, C., Scholes‐Robertson, N., Kelly, A., Craig, J. C., Strippoli, G., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13454 · Cited by 63
“…methods studies that reported the perspectives and experiences of adults ( ≥ 18 years) with type 1 or type 2 diabetes on CGM (including both flash CGM that transmits the data on demand and real-time CGM that sends the data instanta-neously 19 ) without restrictions based on year or study duration.”
Novak, M. T., Yuan, F., & Reichert, W. M. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4097-6 · Cited by 55
Valenzano, M., Cibrario Bertolotti, I., Valenzano, A., & Grassi, G. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001045 · Cited by 34
Metadata
- Authors
- Garg, S. K., & Akturk, H. K.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-06
- Volume
- 19
- Issue
- S3
- Pages
- S-1-S-2
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2055963248
- Cited by
- 34
- References
- 9
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Future of Continuous Glucose Monitoring. https://app.cochat.ai/papers/10.1089/dia.2017.0097
- The paper
- Garg, S. K., & Akturk, H. K. (2017). The Future of Continuous Glucose Monitoring. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2017.0097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.